W

Lilly’s revenue soars 48%, driven by demand for its GLP-1s

商业管理
分享到
Lilly’s revenue soars 48%, driven by demand for its GLP-1s

Lilly’s sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.

Lilly’s revenue soars 48%, driven by demand for its GLP-1s

Source：MarketWatch

友情提醒：請廣大讀者理性看待市場資訊，切實提高風險意識。站內所有內容僅系市場資訊或相關方觀點，不構成任何形式投資建議。

延伸閱讀

Nvidia’s Jensen Huang crisis tests how much of the AI industry depends on one man

Huang’s exit could fray tight bonds among AI businesses. Plus, Oracle’s potential AI catalyst, a $1.5 trillion Social Security stock proposal and what the…

EU DeFi proposals could push users to riskier platforms, says Coinbase exec

Coinbase’s EU policy chief says applying suitability tests beyond crypto lending and borrowing could limit access and fragment liquidity. Source：Cointelegraph

Bitcoin weakness erases September's bullish signal

Your dayahead look for Nov. 12, 2026 Source：CoinDesk

UK bank Griffin raises $20 million to expand into stablecoin payments

The Series B funding round, led by Octagon Partners valued the Londonbased company at more than $100 million. Source：CoinDesk

來源：https://www.marketwatch.com/story/lillys-revenue-soars-48-driven-by-demand-of-its-glp-1s-7361c223